Literature DB >> 8428409

Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD.

S F Kowalsky1, M Echols, M T Schwartz, G R Bailie, E McCormick.   

Abstract

The pharmacokinetics of a single, oral dose of 750 mg of ciprofloxacin were studied in 35 subjects with various degrees of renal function (Group 1, Clcr > or = 80 ml/min; Group II, Clcr 50-79 ml/min; Group III, Clcr 10-49 ml/min) and on hemodialysis (HD) or continuous ambulatory peritoneal dialysis (CAPD). Blood, urine and CAPD dialysate samples were collected over a period of 48 hours after dosing. Data were fitted using non-linear, least squares regression. The mean Cmax was 3.4 +/- 1.0 mg/l and tmax was 2.3 +/- 0.9 hours. The mean AUC in Group I was 14.7 mg.h/l, Group II was 33.7 (p < 0.001), Group III 63.8 (p < 0.001), HD 57.9 (p < 0.0001) and CAPD 44.3 (p < 0.001). Half-life in Group I was 4.6 h, and was shorter than Group III (11.1 h, p < 0.001), HD (13.4 h, p < 0.001) and CAPD (8.9 h, p < 0.001). Total body clearance and renal clearance demonstrated significant differences also. The dialysis clearance in CAPD patients was 0.53 +/- 0.39 l/h. Peritoneal effluent concentrations varied from 0.6 mg/l during the first exchange, to a peak of 2.2 mg/l during the second, to 0.13 mg/l in the 48 hour (9th) exchange. Dosage adjustments of ciprofloxacin in the presence of renal insufficiency are indicated for subjects with a Clcr < 20 ml/min/1.73m2.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8428409

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  5 in total

1.  Influence of renal failure on intestinal clearance of ciprofloxacin in rats.

Authors:  S Dautrey; L Rabbaa; D Laouari; B Lacour; C Carbon; R Farinotti
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

2.  Bioavailability of ciprofloxacin after multiple enteral and intravenous doses in ICU patients with severe gram-negative intra-abdominal infections.

Authors:  S de Marie; M F VandenBergh; S L Buijk; H A Bruining; A van Vliet; J A Kluytmans; J W Mouton
Journal:  Intensive Care Med       Date:  1998-04       Impact factor: 17.440

Review 3.  Clinical pharmacokinetics during continuous ambulatory peritoneal dialysis.

Authors:  C A Taylor; E Abdel-Rahman; S W Zimmerman; C A Johnson
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

4.  Influence of renal failure on ciprofloxacin pharmacokinetics in rats.

Authors:  B Nouaille-Degorce; C Veau; S Dautrey; M Tod; D Laouari; C Carbon; R Farinotti
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

Review 5.  Absorption interactions with fluoroquinolones. 1995 update.

Authors:  B M Lomaestro; G R Bailie
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.